Neotherix' CEO, Dr Mike Raxworthy, has agreed to take on the additional role of Business Development Manager for RegeNer8 - the N8 Centre for Translational Regenerative Medicine - for a fixed term of two years. Dr Raxworthy will combine this with his responsibilities to Neotherix and will devote approximately two days per week to this new role which will have its administrative base at the University of Leeds. RegeNer8 is one of five research centres established by N8 (a partnership between the North of England's eight leading research-intensive universities) through the Northern Way initiative, to promote scientific and economic development in the North. It promotes a collaborative regional approach between industry, academics and clinicians and aims to accelerate the development of regenerative therapies and bring them through to clinic and market. RegeNer8 will do this by addressing barriers to translation and facilitating collaborations between the excellent academic base available within the N8 Universities and organisations seeking the commercial and clinical application of this technology in regenerative medicine. Links to RegeNer8  and N8 |
